Liotta Conducting Virologic Analysis Of SARS-CoV-2
Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), is conducting virologic analyses of SARS-CoV-2 on non-infectious/pre-inactivated clinical samples using FDA-cleared (Emergency Use Authorized) commercial PCR platforms.
As part of this work, CAPMM researchers are providing space and necessary laboratory information management systems (LIMS) in their College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) facility for the project tasks.
CAPMM researchers are also providing time and expertise for maintaining CAP/CLIA paperwork and associated regulatory requirements.
Liotta received $16,283 from TruGenomix Health, LLC, for this project. Funding began in July 2020 and will end in late June 2021.